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Abstract. An early phase clinical trial is the first step in evaluating
the effects in humans of a potential new anti-disease agent or combi-
nation of agents. Usually called “phase I” or “phase I/II” trials, these
experiments typically have the nominal scientific goal of determining an
acceptable dose, most often based on adverse event probabilities. This
arose from a tradition of phase I trials to evaluate cytotoxic agents
for treating cancer, although some methods may be applied in other
medical settings, such as treatment of stroke or immunological diseases.
Most modern statistical designs for early phase trials include model-
based, outcome-adaptive decision rules that choose doses for successive
patient cohorts based on data from previous patients in the trial. Such
designs have seen limited use in clinical practice, however, due to their
complexity, the requirement of intensive, computer-based data moni-
toring, and the medical community’s resistance to change. Still, many
actual applications of model-based outcome-adaptive designs have been
remarkably successful in terms of both patient benefit and scientific
outcome. In this paper I will review several Bayesian early phase trial
designs that were tailored to accommodate specific complexities of the
treatment regime and patient outcomes in particular clinical settings.
Key words and phrases: Adaptive design, Bayesian design, clinical
trial, dose-finding, phase I trial, phase I/II trial.
1. INTRODUCTION
1.1 An Early Phase Trial
Clinical trials are much more complex than typ-
ical statistical designs may indicate. An example
is a phase I stem cell transplantation (SCT) trial
in which the continual reassessment method (CRM,
O’Quigley, Pepe and Fisher, 1990; O’Quigley, 1990)
was applied to optimize the per-administration dose
(PAD) of gemcitabine, dG, when added to an estab-
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lished two-agent preparative regimen consisting of
intravenous busulfan and melphalan (Andersson et
al., 2002). The design was used for each of two sepa-
rate, parallel trials, one for allogeneic transplant (al-
lotx), which uses stem cells from a matched donor,
and one for autologous transplant (autotx), which
uses the patient’s own stem cells. For each patient,
during the period from day −10 to day −1 preced-
ing the SCT on day 0, each of the three agents was
given on two or more days using a particular sched-
ule and PAD. Previously, a six-day schedule of addi-
tional gemcitabine had been tried, but it was found
to be too toxic, so in this trial each patient’s as-
signed dG was given in a two-day schedule, on each
of days −8 and −3, for total gemcitabine dose 2dG.
“Toxicity” was defined to be any regimen-related
grade 4 or 5 adverse event (AE) occurring within
30 days post transplant and affecting a vital organ,
but excluding AEs that occur routinely in SCT, such
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as marrow suppression and, in allotx, graft-versus-
host disease (GVHD). Using the usual CRM crite-
rion, the design’s nominal goal was to find dG from
a predetermined set of 10 PADs ranging from 225
to 3675 mg/m2 having toxicity probability, pi(dG, θ),
with posterior mean Eθ{pi(dG, θ)|data} closest to the
target 0.10, where θ denotes the model parameters.
The principal investigator (PI) specified the conser-
vatively low target 0.10 in part due to the previ-
ous negative experience with the six-day schedule,
and also because 0.10 is consistent with the toxi-
city rate of the established two-agent regimen. In
each subgroup, gemcitabine doses were to be chosen
for successive cohorts of 3 patients, up to a maxi-
mum of 36 patients, with the safety rules that no
untried dose could be skipped when escalating and
accrual to the subgroup would be stopped if the low-
est dose dG = 255 was unacceptably toxic, formally
if Pr{pi(225, θ)> 0.10|data}> 0.80.
Because clinical trials are medical experiments with
human subjects, they often do not play out precisely
as designed. In the course of this trial: (i) when
no toxicity was seen in the first 24 patients the PI
decided to change the two-day gemcitabine sched-
ule (−8,−3) to the three-day schedule (−8,−6,−3)
while maintaining the same total dose by giving 23dG
on each day, (ii) this three-day schedule was quickly
found to cause severe skin toxicity in the first few
patients who received it and accrual was suspended,
and (iii) we re-designed the trial again by returning
to the two-day schedule, but (iv) at the PI’s request
we also expanded the set of possible dG values. After
28 allotx patients had been treated and fully evalu-
ated, however, (v) concern about observed grade 3
mucositis and skin toxicities seen at higher dose lev-
els caused the physicians to expand the definition of
“toxicity” to include these events, which previously
had been excluded if they could be resolved thera-
peutically within two weeks. Along with this change,
they also decided to change the CRM target from
0.10 to 0.15. These last changes had the combined
effect of substantially increasing the numbers of pa-
tients with “toxicity” among those treated at higher
dose levels and greatly reducing the value of dG rec-
ommended by the CRM. Per standard regulatory
procedure, it was necessary to obtain institutional
review board approval for each change in the de-
sign. So, this trial actually was designed five times,
it evaluated effects of a combination of three agents
given in overlapping pre-transplant schedules, both
the dose and schedule of gemcitabine were varied
adaptively during the trial using three different for-
mulations of the CRM to choose gemcitabine PADs
and ad hoc decisions for changing schedules, there
were two simultaneous trials involving different SCT
modalities, the dominant effects on toxicity were
both dG and the schedule of gemcitabine, and the
definition of toxicity was changed near the end of the
trial to be more inclusive and thus obtain a more
protective dose selection criterion. Overshadowing
all of this were the actual goals, which were not only
to control toxicity but also to reduce the rate and
severity of GVHD in the allotx patients and to im-
prove the rates of engraftment and 100-day survival,
compared to the established preparative regimen.
1.2 Some Generalities
Denote the treatment administered to a given pa-
tient by x. In the designs discussed here, x will be
the dose of an agent, the dose pair of two agents
given together, or a (schedule, dose) combination
consisting of a finite sequence of administration times
and corresponding doses. Actual patient outcome in
oncology trials is very complex, often including nu-
merous different types of toxicity scored on ordinal
scales of severity (grade), disease status scored as a
binary or ordinal variable, with each often recorded
at several successive evaluations, as well as the times
of delay or discontinuation of treatment, drop-out
or death. In sharp contrast, the outcome Y used for
statistical decision-making during the trial usually
is defined to be a single variable or possibly a vec-
tor of two variables. In the examples given here, the
designs assume that Y is, respectively, a single bi-
nary toxicity indicator, a vector of two binary in-
dicators of toxicity and efficacy, a vector of ordinal
toxicities or a time-to-toxicity variable subject to
right censoring. The model consists of a probability
density function (p.d.f.) or mass function (p.m.f.)
f(y|x, θ) of Y for a patient who receives treatment
x, and a prior p(θ|ξ), where θ is the model param-
eter vector and ξ are fixed hyperparameters. The
data observed from the first n patients in the trial
are Dn = {(x
(1), Y (1)), . . . , (x(n), Y (n))}, with likeli-
hood Ln(Dn|θ) =
∏n
i=1 f(Y
(i)|x(i), θ) and posterior
pn(θ|Dn, ξ)∝Ln(Dn|θ)p(θ|ξ).
All of the designs that I will discuss here utilize
Bayesian “learn-as-you-go” decision rules to choose
x from the set of possible treatments, X , based on
the posterior pn(θ|Dn) computed from the most re-
cent data available when a new patient is enrolled.
Such a sequentially adaptive decision algorithm may
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be expressed as a sequence α = {αn} of functions
αn :Dn→X ∪φ, where φ denotes the empty set and
αn(Dn) = φ means “Do not treat with any x ∈ X .”
In general, {αn} may include several adaptive deci-
sion rules used together, such as rules for choosing a
dose, a dose pair or a (schedule, dose) combination,
for temporarily suspending accrual to wait for ad-
ditional data on previously treated patients, or for
stopping the trial early because no x ∈X is accept-
able. The (n+1)st iteration of the Bayesian medical
decision-making process may be described by the se-
quence of mappings
Dn
(f,p)
−→ pn(θ|Dn, ξ)
αn−→ xn+1
(1)
−→ Yn+1 −→Dn+1
in which Bayes’ Theorem uses the assumed proba-
bility model (f, p) to map the observed data into a
posterior, the decision rules αn use this to choose
the next treatment xn+1, the patient is treated, the
outcome Yn+1 is observed, and (xn+1, Yn+1) are in-
corporated into the data. This process is repeated
until the end of the trial, which may be when ei-
ther a maximum sample size Nmax or trial dura-
tion Tmax is reached, or because the trial is stopped
early. The process whereby the expanding data set is
used by applying Bayes’ Theorem repeatedly to turn
pn(θ|Dn, ξ) into pn+1(θ|Dn+1, ξ) may be called “it-
erative Bayesian learning,” in that one learns about
θ as additional data are observed during the trial.
In the sequel, to simplify notation I will suppress
dependence of the posterior on the prior hyperpa-
rameters ξ.
A design consists of the trial’s entry criteria, treat-
ments X , set of possible patient outcomes, probabil-
ity model (f, p), decision rules α, Nmax or Tmax , and
possibly a cohort size, c. Since αn acts on Dn indi-
rectly through pn(θ|Dn) in Bayesian adaptive de-
signs, evaluation of a design’s properties must ac-
count for the fact that {pn(θ|Dn)} is a sequence of
statistics. The complexity of the process summa-
rized by (1), even for binary Y and a single dose
x, has motivated the routine use of computer sim-
ulation under each of a set of assumed “true” f as
a tool to evaluate the frequentist operating charac-
teristics (OCs) of the design for various α’s. This is
used as a basis for choosing decision rules, calibrat-
ing design parameters, and possibly calibrating the
prior. There is nothing “non-Bayesian” about using
frequentist OCs of a Bayesian design to adjust the
prior and design parameters. On the contrary, be-
cause simulating a trial that is based on a Bayesian
design allows the physician to better understand the
consequences of particular prior values, simulation
provides a tool for the physician to modify his/her
prior so that it more accurately reflects what the
physician actually believes. It also is important to
examine the prior’s properties in the natural param-
eter domain, such as the probability of toxicity at
dose x, pi(x, θ), rather than in terms of elements of
θ that may have no intuitive meaning to a physician.
One should also examine the first few decisions αn
for each of several possible configurations of data,
in order to avoid a prior that does not make sense.
This is especially important for evaluating decisions
that must be made early in the trial based on very
little data, such as choosing the second cohort’s dose
based on data from the first cohort of three patients.
The prior always has consequences in an early phase
trial, regardless of how “uninformative” it may ap-
pear to be.
If one does not wish to use simulation as a design
tool, the most common alternative approach is to
first specify a formal optimality criterion and solve
for α mathematically (cf. Haines, Perevozskaya and
Rosenberger, 2003; Dette et al., 2008). However, the
simulation-based OCs of a design obtained using a
particular optimality criterion are often surprising,
essentially because such a design’s properties are a
consequence of the optimality criterion used. One
may maximize information, minimize the variance
of a particular estimated quantity, minimize mean
or maximum sample size, control false positive or
other incorrect decision probabilities, minimize ex-
pected financial costs, minimize expected trial du-
ration, optimize outcomes for patients in the trial
or for future patients, etc. Since, unavoidably, such
goals often are at odds with each other, use of the
word “optimal” without qualification may be very
misleading.
1.3 Some Practical Issues
Actual clinical trial logistics can be quite com-
plex. While the CRM adaptively chooses a new dose
from a continuum for each new patient, Goodman,
Zahurak and Piantadosi (1995) proposed the prac-
tical modifications of choosing doses for successive
cohorts of several patients and limiting doses to a
finite set. In most of the outcome adaptive dose-
finding applications that I have seen, each newly
chosen x is given to a cohort. Moreover, a “do not
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skip” safety rule often is imposed that does not al-
low an untried dose to be skipped when escalating.
While limiting doses to a finite set of discrete values
usually does not allow the exact MTD to be chosen,
the difference between the chosen dose and the true
MTD may be small, provided that the chosen sizes
doses are reasonable. For example, using the dose
set {100, 200, 400, 800, 1600} must miss an actual
MTD of 600 by at least 200, which is larger than the
difference between the first two doses. Moreover, es-
calation from 400 to 800 or from 800 to 1600 may
be unsafe, regardless of whether a do-not-skip rule
is imposed.
For example, if a cohort size c = 3 is used, then
αn chooses xn+1 = xn+2 = xn+3 and, formally, Yn+1,
Yn+2 and Yn+3 all must be observed before updat-
ing the data and making the next decision. How-
ever, if Yn+1 has been fully evaluated at the time
patient n + 2 is accrued, then xn+2 may be cho-
sen more reliably by applying the decision criterion
based on the updated posterior incorporating the
data (xn+1, Yn+1) from patient n + 1; similarly, if
Yn+1 and Yn+2 are known when patient n+3 is ac-
crued, their data may be included to choose xn+3.
A simple approach that works surprisingly well is to
use the “look ahead” rule: If the possible outcomes
of treated patients for whom Y has not yet been fully
evaluated will not alter the chosen x for the next
patient, then treat the next patient with x without
delay (Thall et al., 1999). This is closely related to
the general fact that the time window required to
evaluate Y per its definition and the accrual rate
together play critically important roles in trial con-
duct. For example, if Y = I (toxicity within 3 months
from start of therapy) and the accrual rate is 6 pa-
tients per month, then any outcome-adaptive rule
based on Pr(Y = 1|x, θ) is virtually useless, since a
large number of patients will be treated before the
rule may be applied. Some possible ways to imple-
ment an outcome-adaptive design in such settings
are as follows: (i) use c = 1 but enroll only a very
small proportion of eligible patients in the trial, (ii)
use c= 3 or larger with accrual suspended between
cohorts, but use the look-ahead rule to improve lo-
gistical feasibility, or (iii) redefine the outcome to be
time-to-toxicity, but use a safety rule that may delay
accrual interimly to allow the data from previously
treated patients to mature (cf. Bekele et al., 2008).
At the start of the trial, when n = 0, the first
treatment x1 may be chosen by applying the de-
cision rule α0 based on the prior p(θ|ξ). Methods
for choosing a starting dose have been proposed by
Goodman, Zahurak and Piantadosi (1995) and Che-
ung (2005). Most commonly, x1 is chosen by the
physician based on the nature of x, the definition of
Y , the trial’s entry criteria and clinical experience
treating the disease. For example, a trial enrolling
prostate cancer patients with a life expectancy of six
years is very different from a trial enrolling brain tu-
mor patients with a life expectancy of six months.
Similarly, depending on the trial’s entry criteria and
treatment, “toxicity” may be defined as anything
from severe fatigue to regimen-related death. It thus
makes sense, during the prior elicitation process, to
calibrate p(θ) so that α0 agrees with the physician’s
x1, since the motivation for choosing a particular x1
is based on prior experience.
In this paper I will review several designs that
focus on the problem of reflecting more fully partic-
ular complexities of (x,Y ). Each design addresses
some, but not all, of the issues in the SCT trial de-
scribed earlier. These methods were motivated by
problems that I have encountered during the pro-
cess of designing early phase trials over the past
19 years. Each design was developed by a collab-
orative team including one or more physicians, one
or more statisticians and a computer programmer.
Each may be called a “phase I” design in that dose-
finding is based on toxicity, or a “phase I/II” de-
sign in that dose-finding is based on both efficacy
and toxicity, with the exception of the design de-
scribed in Section 5 that jointly optimizes schedule
and dose (Braun et al., 2007). While it is tempting
to think that a “one-size-fits-all” design encompass-
ing all phase I/II possibilities may be constructed,
in my experience clinical research is far too com-
plex to do this, and each new trial design problem
often has unique aspects that require a new model
or method. The particular data structure, probabil-
ity model and decision rules that should be used to
design a clinical trial are best determined through
careful discussion with the physicians planning the
trial, and must strike a compromise between the de-
sire to accurately reflect the medical process and ad-
dress scientific goals while accommodating the prac-
tical realities of trial conduct.
I will not discuss methods for eliciting and cal-
ibrating priors, since this topic could easily fill an
additional manuscript. I will not explore the eth-
ical aspects of adaptive decision rules either, since
they also are quite complex (cf. Palmer, 2002). Early
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phase trial design and conduct are difficult and com-
plicated in large part due to the tension between
optimizing the benefit and safety of patients treated
in the trial, and learning about the effects of each
x on Y to benefit future patients, as well as eco-
nomic constraints and regulatory requirements. In
this regard, a statistician constructing an adaptive
design should be mindful of the ethical issues regard-
ing what happens, for example, to patient number
7 because (s)he was treated with x6 based on how
α6 acted on p6(θ|D6).
2. DOSE-FINDING FOR TWO-AGENT
COMBINATIONS
2.1 Outcomes and Models
Thall et al. (TMML, 2003) proposed a method
for determining one or more acceptable dose pairs
x= (x1, x2) of two cytotoxic agents given together,
based on a binary indicator Y of toxicity. To sta-
bilize the model numerically, each dose is standard-
ized so that 0≤ x1, x2 ≤ 1, for example, by dividing
each raw dose by some maximum value, so that each
x ∈X = [0,1]2. The probability model for toxicity is
Pr(Y = 1|x, θ)
≡ pi(x, θ)(2)
=
α1x
β1
1 +α2x
β2
2 +α3x
β1β3
1 x
β2β3
2
1 +α1x
β1
1 +α2x
β2
2 +α3x
β1β3
1 x
β2β3
2
,
where θ = (α1, β1, α2, β2, α3, β3). All elements of θ
are positive valued, which ensures that pi(x, θ) is a
probability and that it is increasing in each entry
of x. Denoting the subvectors θj = (αj , βj) for j =
1,2,3, so that θ = (θ1, θ2, θ3), the model (2) contains
the submodels
pi1(x1, θ1) = Pr{Y = 1|x= (x1,0), θ1}
(3)
=
α1x
β1
1
1 +α1x
β1
1
,
which is the probability of toxicity when agent 1 is
given alone at dose x1 and, similarly,
pi2(x2, θ2) = Pr{Y = 1|x= (0, x2), θ2}
(4)
=
α2x
β2
2
1 +α2x
β2
2
for agent 2 given alone at dose x2. Since αjx
βj
j =
exp{log(αj)+β log(xj)}, (3) and (4) are logistic mod-
els in a log standardized dose. TMML assume that
there is clinical experience with each single agent
when used alone, since this often is a requirement
before investigating a combination in humans. Since
θj parameterizes pij(xj , θj) for j = 1,2 and θ3 pa-
rameterizes interaction between the two agents, a
key element of TMML’s approach is that the priors
p(θ1|ξ1) and p(θ2|ξ2) are informative while p(θ3|ξ3)
is vague. Assuming gamma priors on the elements
of θ for tractability, TMML provide a detailed algo-
rithm for eliciting p(θ1|ξ1) and p(θ2|ξ2), although if
historical data are available, the posteriors from pre-
liminary fits of such data may be used as these pri-
ors for trial design and conduct. Considering pi(x, θ)
geometrically as a response surface over the domain
[0,1]2, this says that there is substantial prior knowl-
edge about each of the two lines {x :x2 = 0} and
{x :x1 = 0} on the edges of the response surface, but
otherwise little is known about the surface, so it is
like a sheet tied down at two edges but otherwise
varying freely. In particular, the meaning of θ1 in
the model pi(x, θ) = pi(x, (θ1, θ2, θ3)) is very different
from its meaning in the submodel pi1(x1, θ1). This
is underscored by the prior effective sample sizes
computed by Morita, Thall and Mueller (2008) for
the gamma priors given by TMML (2003, Section
3), which are 547.3 for p1(θ1|ξ1), 756.8 for p2(θ2|ξ2),
0.01 for p3(θ3|ξ3) and 1.5 for p(θ|ξ). This says that,
with respect to toxicity, a priori a lot is known about
how each agent behaves when used alone, but almost
nothing is known about how the two agents behave
together.
Fig. 1. Isocontours of a dose-toxicity probability surface for
two dimensional dose x= (x1, x2).
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2.2 Decision Criteria
The dose-finding method exploits the following ge-
ometric structure on X = [0,1]2. For each p ∈ (0,1),
the set Xp(θ) = {x :pi(x, θ) = p} is the isocontour of
all dose pairs having toxicity probability p. Several
isocontours for a particular fixed θ are illustrated
in Figure 1. Since Xp(θ) ∩ Xq(θ) = φ if p 6= q and⋃
0≤p≤1Xp(θ) = [0,1]
2, every pair x falls on a unique
Xp(θ) for some p. The interaction term α3x
β1β3
1 x
β2β3
2
in (2) is used instead of the simpler term α3x1x2 in
order to give the model sufficient flexibility to allow
“S” shaped isocontours, as shown in Figure 1.
The design proceeds in two stages. In stage 1,
doses are chosen for successive cohorts from a fi-
nite set of values on the predetermined fixed diag-
onal line L1, shown as the straight line at approxi-
mately 45◦ in Figure 1. The design is robust to the
particular angle of L1, as long as it is not too far
from 45◦. Since the response surface pi(x, θ) increases
in each argument x1 and x2, pi(x, θ) must increase
as x moves up L1 from lower left to upper right.
Given target toxicity probability pi∗, dose-finding in
stage 1 proceeds using the CRM criterion of choos-
ing x for each cohort from the set on L1 to minimize
|E{pi(x, θ)|Dn} − pi
∗|, starting at the lowest dose in
the set, not skipping untried doses when escalating,
and adding additional doses to the set once the first
toxicity is observed. That is, restricting x to L1 in
stage 1 reduces dose selection to a one-dimensional
problem, and a conventional CRM algorithm may
be applied. Geometrically, one may think of stage 1
as walking up and down the toxicity surface, along
L1, looking for dose pairs with toxicity probability
close to pi∗.
In stage 2, x is chosen for successive cohorts from
the random isocontour
Xpi∗(Dn) = {x :E{pi(x, θ)|Dn}= pi
∗}.(5)
Since Xpi∗(Dn) contains infinitely many x, an addi-
tional criterion is needed to choose one x for each
cohort in stage 2. TMML suggest two criteria, one
based on the clinical criterion of “cancer killing po-
tential” and the other the more usual statistical goal
of maximizing Fisher Information. Denoting the el-
ements of θ by θ1, . . . , θ6 for convenience, the Fisher
Information matrix I(x, θ) for dose x has (j, k) entry
{∂pi(x, θ)/∂θj}{∂pi(x, θ)/∂θk}/[pi(x, θ){1−pi(x, θ)}].
Under the Bayesian model, x is chosen to maximize
the posterior mean log determinant of I(x, θ) given
the current data, E[log{det I(x, θ)}|Dn]. Doses are
chosen for successive cohorts in stage 2 by alter-
nating between the two subsets of Xpi∗(Dn) to the
left and right of L1. For each subset, the x op-
timizing cancer killing is determined, the x max-
imizing Fisher Information is determined, the av-
erage of these two dose pairs is computed, and the
x ∈Xpi∗(Dn) closest to this average is assigned to the
cohort. At the end of the trial, any x ∈ Xpi∗(Dn) is
a solution. Thus, for example, one may choose three
final dose pairs on Xpi∗(DN ), one on L1, one to the
left of L1 and one to the right of L1, and randomize
patients among these three x pairs in a subsequent
phase II trial.
In their illustrative application, TMML use a co-
hort size of 2 with 60 patients divided into N1 = 20
(10 cohorts) in stage 1 and N2 = 40 (20 cohorts)
in stage 2. Simulations show that using (N1,N2)
either (30, 30) or (40, 20) gives a design with in-
ferior properties compared to (20, 40). Cohort-by-
cohort computations show that the target isocon-
tour Xpi∗(Dn) varies substantially with each new co-
hort’s data even after n= 30 or 40 patients, but sta-
bilizes by n = 50 or 60. This is the case essentially
because a binary outcome is a very small amount
of information per patient. For total sample size
N = N1 + N2 = 60, however, the method is quite
reliable in terms of choosing dose pairs that have
true toxicity probability close to pi∗.
3. USING BOTH EFFICACY AND TOXICITY
From a clinical perspective, the primary purpose
of treatment is to fight disease, and safety is never
a secondary concern in any medical setting. Thus,
both scientifically and medically, both efficacy and
toxicity matter at all stages of clinical investigation.
In many dose-finding trials, the entry criteria spec-
ify patients with such poor prognosis that response
is very unlikely, between 4% and 10%. In such set-
tings, targeting even a low response rate piR∗ = 0.10
or 0.20 and using a phase II type rule to stop ac-
crual if the observed response rate is likely to be
below piR∗ at any acceptable dose may be imprac-
tical, since few or no responses are expected. This
is the most common rationale for conducting phase
I based on toxicity alone, while recording data on
biological effects and possible clinical anti-disease
effects. However, actual response rates vary widely
between phase I trials, and many have complete or
partial response rates well over 20% (cf. Horstmann
et al., 2005). Moreover, patients enroll in a phase
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I trial motivated by the hope that the new treat-
ment will achieve an anti-disease effect, not simply
the desire that no toxicity will occur.
3.1 Outcomes and Models
These considerations lead to the idea that, when
it is realistic to target a response rate of 10% or
larger, dose-finding should be done using a phase
I/II design based on both E = efficacy and T =
toxicity. Many phase I/II designs have been pro-
posed (Gooley et al., 1994; O’Quigley, Fenton and
Hughes, 2001; Braun, 2002; Ivanova, 2003). The fol-
lowing phase I/II methodology, “EffTox,” is based
on the developments given by Thall and Russell
(1998) and Thall and Cook (2004). Illustrations are
given by Thall, Cook and Estey (2006) and Whe-
lan et al. (2008). Patient outcome may be either
a three-category or bivariate binary variable. The
former case applies when E and T are defined in
such a way that they are disjoint but E 6= T c, so
that Y takes on values in {E,T,N} where N =
(E ∪ T )c = {no response and no toxicity}. This is
appropriate if, for example, toxicity is irreversible
organ damage or regimen-related death. When it is
possible for both E and T to occur, the outcome is
bivariate binary, Y = (YE , YT ), where Yk indicates
the outcome k = E,T. For either case, denote the
outcome probabilities for a patient given dose x by
pi(x, θ) = (piE(x, θ), piT (x, θ)).
For the trinary outcome case, the three-parameter
model used by Thall and Russell (1998) is motivated
by the idea that the three outcomes are ordered
in the sense that N < E < T , with the idea that
higher x is more likely to push the patient’s out-
come upward along this scale. The model is given
by piT (x, θ) = g
−1(β0+β2x) and piE(x, θ) = g
−1(β0+
β1+ β2x)− piT (x, θ), where g is a link function, θ =
(β0, β1, β2) and β1, β2 > 0. This model forces piE(x, θ)
to be very nonmonotone in x. A more flexible four-
parameter model (Thall and Cook, 2004, Section 3)
is given by Pr(E|T c, x, θ) = g−1(βE,0 + βE,1x) and
piT (x, θ) = g
−1(βT,0 + βT,1x), where θ = (βE,0, βE,1,
βT,0, βT,1) and βE,1, βT,1 > 0. Using this model,
piE(x, θ) = Pr(E|T
c, x, θ){1 − piT (x, θ)}. For either
model, f(Y |x, θ) =
∏
y=E,N,T{piy(x, θ)}
I(Y=y).
For the bivariate binary case, the model must spec-
ify the four elementary outcome probabilities pia,b(x,
θ) = Pr(YE = a,YT = b|x, θ) for a, b ∈ {0,1}. The
p.m.f. of a patient treated at dose x is f(Y |x, θ) =∏1
a=0
∏1
b=0{pia,b(x, θ)}
I(YE=a,YT=b). The general ap-
proach used by Thall and Cook (2004) and Thall,
Nguyen and Estey (2008) is to first specify the two
marginal dose-outcome distributions pik(x, θ) =
g−1{ηk(x, θ)}, in terms of link function g and linear
terms ηk(x, θ) for k =E and T , and then define the
joint distribution in terms of the marginals. Tem-
porarily suppressing x and θ, pia,b is determined by
(a, b, piE, piT , ψ), where ψ is an association param-
eter. This may be done tractably using a Gumbel
distribution,
pia,b = pi
a
E(1− piE)
1−apibT (1− piT )
1−b
+ (−1)a+bpiE(1− piE)(6)
· piT (1− piT )
(
eψ − 1
eψ + 1
)
,
with ψ real-valued, or a Gaussian copula, C(u, v) =
Φψ(Φ
−1(u),Φ−1(v)), for 0 ≤ u, v ≤ 1, where Φψ is
the bivariate standard normal c.d.f. with correlation
ψ and Φ is the univariate N(0,1) c.d.f. Under this
copula, pi0,0 = Φψ(Φ
−1(1 − piE),Φ
−1(1 − piT )) with
pi1,0 = 1 − piT − pi0,0, and pi1,1 = piE + piT + pi0,0 −
1. If g is the probit link, pik = Φ(ηk) and pi0,0 =
Φψ(−ηE ,−ηT ).
A major practical issue is that the ηk(x, θ)’s should
be realistic but the model must be numerically trac-
table, to facilitate the processes of fitting historical
data if available, prior elicitation, and computing
posterior decision criteria thousands of times while
simulating the trial during the design process. It of-
ten is important to allow piE(x, θ) to be nonmono-
tone in x, which may be appropriate for biological
agents, such as viral vectors expressing cytokines
aimed at triggering an immune response to kill tu-
mor cells. This may be done very effectively by as-
suming a simple quadratic ηE(x, θ) = βE,0+xβE,1+
x2βE,2, although other functions may be used. While
ηT (x, θ) = βT,0 + xβT,1 with Pr(βT,1 > 0) = 1 is ap-
propriate for cytotoxic agents, in other settings a
quadratic also may be used for ηT (x, θ). For ex-
ample, if “toxicity” includes infection and an anti-
cancer agent also kills bacterial or fungal infections,
then piT (x, θ) may be nonmonotone and actually de-
crease with higher x.
Thall and Cook (2004) provide a penalized least
squares method for establishing the prior p(θ|ξ) based
on elicited means µ
(e)
y,j and standard deviations (s.d.’s)
σ
(e)
y,j of piy(xj , θ) for y =E,T and several doses x1, . . . ,
xm. Since each prior mean µy,j(ξ) and s.d. σy,j(ξ) of
piy(xj , θ) is a function of the fixed hyperparameters
ξ characterizing p(θ|ξ), nonlinear least squares may
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be used to solve for ξ by minimizing the objective
function
SS(ξ) =
∑
y=E,T
m∑
j=1
[{µ
(e)
y,j − µy,j(ξ)}
2
+ {σ
(e)
y,j − σy,j(ξ)}
2](7)
+ c
∑
1≤j<k≤m
{σ˜j − σ˜k}
2,
where each σ˜k is a prior standard deviation in ξ.
The second sum in (7) is included to limit the vari-
ability among the prior s.d.’s, using a small penalty
constant c > 0.
3.2 Dose Admissibility and Efficacy-Toxicity
Trade-offs
The dose-finding algorithm relies on two different
types of posterior decision criteria to choose x from
a finite set of possibilities, X = {x(1), . . . , x(k)}. The
first criterion determines which doses are acceptable,
and the second chooses the best acceptable dose. Let
piE be a fixed lower limit on piE(x, θ) and piT a fixed
upper limit on piT (x, θ). The fixed limits are speci-
fied by the physician. Let p∗E and p
∗
T both be fixed
upper probability cut-offs, usually selected from the
range 0.80 to 0.95. A dose x is unacceptable if it
is likely to have either unacceptably low efficacy or
unacceptably high toxicity, formally if
Pr{piE(x, θ)< piE|Dn}> p
∗
E or
(8)
Pr{piT (x, θ)> piT |Dn}> p
∗
T .
A dose x is acceptable if neither inequality in (8)
holds. The set of acceptable doses in X based on
Dn is denoted by An. These criteria are essentially
those used by Thall, Simon and Estey (1995) as
stopping rules in phase II trials, and the second cri-
terion in (8) is used routinely for deciding whether
to stop a phase I trial, for example, when using
the CRM, if the lowest dose is too toxic. For exam-
ple, when using EffTox, if p∗E = p
∗
T = 0.90, the rules
in (8) are equivalent to saying that x is acceptable
if Pr{piE(x, θ) > piE|Dn} > 0.10 and Pr{piT (x, θ) <
piT |Dn} > 0.10. While, intuitively, these may seem
like rather weak requirements, if one replaces 0.10
by a large cut-off such as 0.80 by setting p∗E = p
∗
T =
0.20 in (8), then the rules are nearly certain to stop
any trial very quickly after a very small number of
patients, due to the large variability of the poste-
rior probabilities used in (8). This gets at the im-
portant distinction between determining the accept-
ability of x for the purpose of dose-finding with
small to moderate sample sizes, and the confirma-
tory statement “x is safe and effective” formalized
by inequalities such as Pr{piE(x, θ)>piE|Dn}> 0.95
and Pr{piT (x, θ) < piT |Dn} > 0.95. Such confirma-
tory conclusions are inappropriate based on early
phase trial results since they can only be established
convincingly by a large sample size, regardless of
what the posterior probabilities may be.
To describe the second decision criterion, for sim-
plicity, I will focus on the bivariate binary case,
where pi(x, θ) ∈ [0,1]2. To compare two acceptable
doses, say, x(1) and x(2), based on the posteriors
of pi(x(k), θ) = (piE(x
(k), θ), piT (x
(k), θ)) for k = 1,2,
some method for reducing each pair pi(x(k), θ) to a
one-dimensional criterion is required, as inevitably is
the case when a statistic of dimension ≥ 2 is used for
comparison. The EffTox method does this by formal-
izing the idea that a higher risk of toxicity is a rea-
sonable trade-off for a higher probability of achiev-
ing anti-disease effect. The method first computes
the posterior means µ(n)(x) = (µ
(n)
E (x), µ
(n)
T (x)) =
(E{piE(x, θ)|Dn},E{piT (x, θ)|Dn}) for each x ∈ X .
Each µ(n)(x) is then reduced to a one-dimensional
criterion by the following geometric construction,
which begins by eliciting several pairs of fixed proba-
bilities, p(j) = (p
(j)
E , p
(j)
T ), j = 1, . . . ,m, that the physi-
cian considers equally desirable. A target curve, C,
is fit to the elicited pairs, treating pT as a monotone
increasing function of pE , or, equivalently, reversing
the roles of pT and pE . This should be done using
a graphical representation of C to provide a means
for the physician to adaptively modify his/her target
pairs. Given p ∈ [0,1]2, let pC denote the point where
the straight line segment in [0,1]2 passing through
p and the ideal point (1, 0) intersects C. The desir-
ability of p may be defined as
δ(p) = exp
{
−
‖p− (1,0)‖
‖pC − (1,0)‖
}
,(9)
where ‖ · ‖ denotes Euclidean distance. This has
maximum δ(1,0) = 1, with δ(p) decreasing as pmoves
away from (1, 0) along any straight line in [0,1]2.
Several other definitions of δ(p) may be used, al-
though (9) is reasonable and tractable. The contour
of all p having desirability u is Cu = {p ∈ [0,1]
2 : δ(p) =
u}, so that C = Ce−1 . Denote the set of real num-
bers u such that Cu 6= φ by RC . Since u 6= v =⇒
Cu∩Cv = φ, the family {Cu, u ∈RC} partitions [0,1]
2.
This construction is used to quantify the desirabil-
ity of a dose x by evaluating (9) at p= µ(n)(x). To
compare doses x(1) and x(2), we compute µ(n)(x(1))
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Fig. 2. Example of posterior means µ(n)(x(j)) = (E{piE(x
(j), θ)|datan}, E{piT (x
(j), θ)|datan}) for two dose pairs x
(1) and
x(2) (denoted by round dots), given alone in the left-hand graph (Figure 2a), and with the addition of the target contour C
constructed from elicited target points (denoted by ×) and several resulting desirability contours (Figure 2b).
and µ(n)(x(2)), illustrated by the two round dots
in Figure 2a, and then compute their desirabilities
δ(µ(n)(x(1))) and δ(µ(n)(x(2))), as shown in Figure 2b.
The elicited pairs are represented by the symbol
“×” in Figure 2b, which also shows C and several
Cu along with their numerical u values. During the
trial, if no dose is acceptable, formally if An = φ,
then accrual is stopped with no dose selected; oth-
erwise each cohort is given the dose x maximizing
δ(µ(n)(x)) among all x ∈An. This methodology has
been used for dose-finding trials in acute stroke,
treatment for GVHD in SCT, chemotherapy of acute
leukemia, and anergized cells given post-transplant
to accelerate immune reconstitution following allotx.
It is important to consider the consequences of
how one sets goals in the bivariate binary outcome
case. Recall that pia,b =Pr(YE = a,YT = b) with piE =
pi1,1+pi1,0 and piT = pi1,1+pi0,1. Several authors have
proposed choosing x to maximize pi1,0, the prob-
ability of the best possible outcome, efficacy and
no toxicity, or the conditional probability piE|T c =
pi1,0/(1− piT ). Unfortunately, most new treatments
simply don’t work that way. A new therapy that is
either more aggressive, for example, a higher dose,
or highly active biologically is likely to decrease pi0,0
and increase some combination of pi1,0, pi0,1 and pi1,1.
Treating pi = (pi0,0, pi1,0, pi0,1, pi1,1) as fixed for sim-
plicity, suppose that standard treatment gives out-
come probability vector pi(0) = (0.50,0.10,0.30,0.10),
which has marginals (piE , piT ) = (0.20,0.40). Suppose
that experimental treatment x(1) has pi(1) = pi(x(1)) =
(0.30,0.20,0.30,0.20), which has marginals (pi
(1)
E ,
pi
(1)
T ) = (0.40,0.50), a doubling of pi
(0)
E from 0.20 to
0.40 and a 25% increase in pi
(0)
T from 0.40 to 0.50.
Suppose that a competing experimental treatment
x(2) has pi(2) = pi(x(2)) = (0.30,0.20,0.45,0.05), which
has marginals (pi
(2)
E , pi
(2)
T ) = (0.25,0.50), a slight in-
crease in pi
(0)
E from 0.20 to 0.25 with the same in-
crease in pi
(0)
T as given by x
(1). Since pi1,0(x
(1)) =
pi1,0(x
(2)) = 0.20 and piE|T c(x
(1)) = piE|T c(x
(2)) = 0.40,
a method based on either pi1,0 or piE|T c would con-
sider x(1) and x(2) to be equivalent. In contrast, the
trade-off based method would consider x(1) superior
to x(2).
4. FINDING PATIENT-SPECIFIC DOSES
Thall, Nguyen and Estey (2008) generalized EffTox
to account for patient heterogeneity by using the
patient’s vector Z = (Z1, . . . ,Zq) of covariates ob-
served at enrollment. The method requires historical
data, H, to obtain an informative distribution on co-
variate effect parameters for use in trial design and
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conduct. The model and method account for dose
effects, covariate effects and possible dose-covariate
interactive effects on piE and piT . The design assigns
each patient a dose that is individualized based on
the patient’s Z vector. This is very different from
conventional early phase trial designs, since (i) pa-
tients with different covariates may receive different
doses at the same point in the trial, (ii) the entry
criteria may change adaptively, with the possibility
that enrollment may be shut down for some patients
but continued for others, and (iii) at the end of the
trial a computer-based rule is provided for assigning
each future patient’s x based on his/her Z vector,
rather than choosing a single dose for all patients.
For designs with individualized treatment assign-
ment rules utilizing Z (cf. Ratain et al., 1996; Babb
and Rogatko, 2001), the ith patient’s data are (x(i),
Z(i), Y (i)), the probability model is elaborated by
defining f(y|Z,x, θ) for a patient with covariates
Z who receives treatment x, and αn is a function
of (Z,Dn). To accommodate Z and historical data
in the design described here, let τ denote either a
dose x in the trial or historical treatment from the
set {τ1, . . . , τm}. The probability model given ear-
lier is extended by defining the marginal probabil-
ities, pik(τ,Z, θ) = g
−1{ηk(τ,Z, θ)}, k = E,T, for a
patient with covariates Z given dose x, assuming
linear terms of the general form
ηk(τ,Z, θ) = βkZ +
m∑
j=1
(µk,j + ξk,jZ)I(τ = τj)
(10)
+ {ωk(x,αk) + γkZ}I(τ = x)
for k = E,T , where βkZ = βk,1Z1 + · · ·+ βk,qZq ac-
count for covariate main effects, γkZ = γk,1Z1+ · · ·+
γk,qZq account for dose-covariate interactions, µk =
(µk,1, . . . , µk,m) are historical main treatment effects,
ξk,jZ = ξk,j,1Z1+ · · ·+ ξk,j,qZq account for covariate
interactions with the jth historical treatment, and
ωE(x,αE) and ωT (x,αT ) are the usual dose-outcome
functions characterizing main dose effects, and ωE
and ωT may be quadratic or linear functions of x,
as given earlier. For fitting the historical data, (10)
takes the form
ηk(τj,Z, θ) = µk,j + βkZ + ξk,jZ
(11)
for j = 1, . . . ,m and k =E,T.
For fitting the data obtained during the trial, (10)
is
ηk(x,Z, θ) = ωk(x,αk) + βkZ + xγkZ
(12)
for k =E,T.
A much more parsimonious model that accounts
for dose-covariate interactions is obtained by replac-
ing xγkZ in (12) with either γk{ωk(x,αk)×βkZ} or
γk{x×βkZ} where each γk is now a single parameter
rather than a q-dimensional vector. This model re-
quires only 2 dose-covariate interaction parameters
instead of 2q. This is motivated by the idea that
γk{ωk(x,αk)× βkZ} is similar to the one-degree of
freedom interaction term in the model for a two-
way layout with one observation per cell given by
Tukey (1949). Unfortunately, in practice, this par-
simonious model is a complete disaster since, using
either ωk(x,αk) or x, it gives a very poor fit to the
trial data when dose-covariate interactions of any
complexity are present. So this more parsimonious
model is a cute idea that simply doesn’t work.
Generalizing the EffTox design to accommodate
Z requires much more than writing down a model.
The set An(Z) of acceptable doses for a patient with
covariates Z is defined to be all x ∈X satisfying the
constraints
Pr{piE(x,Z, θ)< piE(Z)|Dn ∪H}< p
∗
E and
(13)
Pr{piT (x,Z, θ)>piT (Z)|Dn ∪H}< p
∗
T ,
where piE(Z) and piT (Z) are acceptability bounding
functions, constructed as follows. First, a represen-
tative set of covariate vectors, {Z(1), . . . ,Z(K)}, is
determined. For each Z(j), the physician specifies
the smallest probability of efficacy, pi
(j)
E , and the
largest probability of toxicity, pi
(j)
T , that are accept-
able for a patient having those covariates. For k =
E,T, denote ζk(Z) = E(βkZ|H), the historical pos-
terior mean of the covariate main effect linear com-
bination. To construct the bounding function piE(Z)
for piE(x,Z, θ), the K pairs (ζE(Z
(1)), pi
(1)
E ), . . . ,
(ζE(Z
(K)), pi
(K)
E ) of estimated linear terms and elicited
lower bounds on piE are used as regression data to fit
a simple linear or quadratic curve by least squares,
using ζE(Z
(j)) as the predictor and pi
(j)
E as the out-
come variable. Denoting the estimated outcome un-
der the fitted regression model by pˆiE(ζE(Z)), the
efficacy lower bounding function is piE(Z) = pˆiE ◦
ζE(Z). The toxicity upper bounding function piT (Z) =
pˆiT ◦ ζT (Z) is computed similarly from (ζT (Z
(1)),
pi
(1)
T ), . . . , (ζT (Z
(K)), pi
(K)
E ). When constructing these
functions, it is important to plot the scattergrams of
the constructed regression data sets along with the
fitted curves, which the physician may use to guide
adjustment of some pi
(j)
E or pi
(j)
T values, if desired, to
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obtain acceptability bounding functions piE(Z) and
piT (Z) that make sense clinically. These construc-
tions map each patient’s Z vector into the probabil-
ity bounds used in (13) to determine whether each
x ∈ X is acceptable for that patient. To define a
covariate-specific dose desirability index, we evalu-
ate δ(p) given by (9) at p= µ(n)(x,Z) = (E{piE(x,Z,
θ)|Dn},E{piT (x,Z, θ)|Dn}), and denote this by
δn(x,Z). For two patients with different covariates
Z1 6= Z2, it may be the case that An(Z1) 6=An(Z2),
including the possibility that An(Z) = φ for one pa-
tient but not the other. Even if An(Z1) =An(Z2),
the x that maximizes δn(x,Z1) may not be the same
as that maximizing δn(x,Z2).
Figure 3 illustrates how the dose-efficacy and dose-
toxicity probability curves in x also may change
with Z. The curves are given for a particular fixed
θtrue in which the interactive effects of x and Z are
substantial, taken from the acute leukemia applica-
tion discussed by Thall, Nguyen and Estey (2008)
where Z = (AGE, cytogenetic abnormality), with
the second covariate coded as a three-category vari-
able having possible values {Good, Intermediate,
Poor} defined in terms of prognostic level. The rows
in Figure 3 correspond to three different Z values. In
the left column, the probabilities piE(x, θ) are repre-
sented by circles and piT (x, θ) by triangles, with an
open (filled) circle or triangle representing an unac-
ceptable (acceptable) dose. The corresponding desir-
abilities are given in the right column, obtained by
evaluating δ(piE(x,Z, θ
true), piT (x,Z, θ
true)). The fig-
ure shows that the dose-outcome functions piE(x, θ)
and piT (x, θ) may change dramatically with Z, that
the effect of prognosis may be as large as or larger
than that of dose, and that interactions between x
and Z may be quite important. Figure 3 also illus-
trates how the desirability function δ reduces each
two-dimensional (pE , pT ) to a one-dimensional value
that may be used to compare doses for each Z.
To apply this methodology, the first step is to
analyze H under several models, choose the model
providing the best fit, compute p(β, ψ|H), and de-
termine noninformative priors on α and γ. During
the trial, when a patient with covariates Z is en-
rolled, An(Z) is computed. IfAn(Z) = φ, the patient
is not treated on protocol. If An(Z) 6= φ, the patient
is treated with the dose x maximizing δn(x,Z). If
An(Z
(j)) = φ for all representative covariates, then
the trial is stopped. After the trial, given final data
DN , the decision rules based on p(θ|H ∪ DN ) are
used to select doses for future patients.
Our computer simulation studies of this new
methodology have produced some disquieting mes-
sages. The first is that ignoring established prog-
nostic covariates may lead to either very unsafe or
very ineffective dose assignments for many patients
both during and after a phase I or phase I/II trial.
The second message is that, if dose-covariate inter-
actions are present, ignoring them by using an addi-
tive model for the effects of x and Z also may lead
to very poor dose assignments. That is, the common
practice of ignoring known patient heterogeneity in
early phase trials may lead to bad science and bad
clinical practice.
5. ACCOUNTING FOR MULTIPLE
TOXICITIES
5.1 Outcomes and Model
Bekele and Thall (BT, 2004) proposed a dose-
finding method based on a vector Y = (Y1, . . . , YJ) of
several qualitatively different types of toxicity, with
Yj an ordinal variable recording the jth toxicity’s
severity. The method was motivated by a phase I
trial to choose a dose of gemcitabine, in mg/m2,
from {100, . . . ,1000} when combined with a fixed
dose of 50 cGy external beam radiation, both given
prior to surgery, for patients with soft tissue sar-
coma. The design was developed working with a
team of three oncologists who had extensive expe-
rience treating sarcomas. The point of departure
from conventional methods is that the design dis-
tinguishes between different types of toxicity, and it
also accounts for the severity levels of each.
Denote themj+1 severity levels of Yj by {yj,0, yj,1,
. . . , yj,mj}. For example, in the sarcoma trial the 4
levels of liver toxicity were yj,0 = {grade 0 or 1},
yj,1 = {grade 2}, yj,2 = {grade 3} and yj,3 = {grade 4}.
Binary Yj corresponds to mj = 1. Using standard-
ized doses x = log{(raw dose)/1000}, so that X =
{−2.30,−1.61, . . . ,0}, the distribution of Y |x was
modeled using the method of Albert and Chib (1993),
in terms of the J -vector of Gaussian latent variables
ζ = (ζ1, . . . , ζJ) with E(ζj|x) = βj,0+xβj,1, var(ζj) =
1 and correlation matrix Ω, by defining Yj = yj,k if
γj,k ≤ ζj < γj,k+1 for k = 0,1, . . . ,mj and j = 1, . . . , J
for cut-off parameters γj = (γj,1, . . . , γj,mj) satisfy-
ing −∞ = γj,0 < γj,1 < · · · < γj,mj < γj,mj+1 = +∞,
with γj,1 ≡ 0 to ensure identifiability. This formula-
tion greatly facilitates MCMC computations used to
obtain posterior quantities. Denoting the 2J -vector
of regression parameters β = (β1,0, β1,1, . . . , βJ,0, βJ,1),
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Fig. 3. Marginal outcome probabilities piE(x, θ), given as circles, and piT (x, θ), given as triangles (left column) and corre-
sponding desirabilities (right column) for each of three different patient prognostic vectors, under a fixed θ. Solid (open) points
correspond to acceptable (unacceptable) doses.
the vector γ = (γ1, . . . , γJ) having m+ =m1 + · · ·+
mj entries, and the J(J−1)/2 off-diagonal elements
of Ω by ρ= (ρ1,2, ρ1,3, . . . , ρJ−1,J), the model param-
eter vector is θ = (β, γ, ρ). The marginal distribution
of Yj |x is given by
pij,k(x, θ) = Pr(Yj = yj,k|x, θ)
= Φ(γj,k+1− βj,0− βj,1x)(14)
−Φ(γj,k − βj,0− βj,1x).
To obtain an expression for the joint distribu-
tion, denote the p.d.f. of a multivariate normal ran-
dom vector W with mean vector µ and variance–
covariance matrix Σ by φW (·|µ,Σ). In matrix no-
tation, E(ζ|x) =Xβ′, where X is the J × 2J block
diagonal matrix with J identical blocks ( 1 x ). De-
note the intervals Gj,k = (γj,k, γj,k+1]. For observed
vector k = (k1, . . . , kJ) of toxicity severity levels, the
outcome is Y = y(k) = (y1,k1 , . . . , yJ,kJ ), which cor-
responds to latent ζ values in the J -dimensional set
G(k, γ) =G1,k1 × · · ·×GJ,kJ . A single patient’s like-
lihood contribution is
L(Y |x, θ)
=
m1∏
k1=0
· · ·
mJ∏
kJ=0
{∫
G(k,γ)
φZ(z|Xβ
′,(15)
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Ω)dz
}I[Y=y(k)]
.
For priors, BT assume β ∼ N(µ,Σ), subject to
Pr(βj,1 > 0) = 1 for all j = 1, . . . , J, so that β is 2J -
variate normal with all slope coefficients truncated
below at 0, but µ and Σ correspond to the untrun-
cated 2J -variate normal. This ensures that Pr(Yj >
yj,k|x,β) = 1−Φ{γj,k − βj,0 − βj,1x} increases with
x for each j and k > 1. For each j with mj ≥ 2
(3 or more levels), {γj,2, . . . , γj,mj} follow indepen-
dent, uninformative priors on the domain [0,10],
with each p(γj,k)∝ 1, subject to the constraint 0<
γj,2 < γj,3 < · · ·< γj,Cj , where the upper limit 10 on
the support of each p(γj,k) was chosen for numeri-
cal convenience. The ρj,k’s are assumed to be i.i.d.
N(0,1000), truncated to have support [−1,+1], with
Ω positive definite.
5.2 Total Toxicity Burden and Trial Conduct
The dose-finding method is based on toxicity sever-
ity weights, elicited as follows. The oncologists are
first asked to specify the J toxicities to be moni-
tored, including the severity levels of each. They are
then asked to specify a numerical severity weight for
each level of each toxicity within a positive-valued
numerical range with which they are comfortable,
such as 0 to 10, or 0 to 100. The severity weights
are denoted by w = (w1, . . . ,wJ), where wj = (wj,0,
wj,1, . . . ,wj,mj) are the severity weights of the possi-
ble values (yj,0, yj,1, . . . , yj,mj) of Yj, with the obvi-
ous requirement wj,0 <wj,1 < · · ·<wj,mj ; otherwise,
if wj,k =wj,k+1, then levels k and k+1 of Yj should
be combined. The elicited severity weights used in
the sarcoma trial are illustrated in Figure 4. An in-
teresting practical point arose while assigning sever-
ity weights to myelosuppression, which is defined in
terms of low blood cell counts and is caused by ef-
fects of chemotherapy on the bone marrow. At first,
no distinction was made between myelosuppression
occurring either with or without fever. During the
process of establishing w, however, the oncologists
explained that myelosuppression is much more se-
vere when it occurs with fever, since it is then life-
threatening and may be an impediment to further
chemotherapy. This led us to redefine myelosuppres-
sion occurring without or with fever as two different
types of toxicity. Figure 4 shows the severity weights
1 and 1.5 for grade 3 and 4 myelosuppression with-
out fever, compared to weights 5 and 6 for grade
3 and 4 myelosuppression with fever. Thus, in gen-
eral, Y and w are elicited together, and this process
is not unlikely to involve iteration.
A patient’s total toxicity burden (TTB) is defined
to be
TTB =
J∑
j=1
mj∑
k=1
wj,kI(Yj = yj,k).(16)
For example, from Figure 4, a patient with grade 3
fatigue, grade 3 nausea/vomiting and grade 4 myelo-
suppression without fever would have TTB = 0.5 +
1.5+1.5 = 3.5, whereas a patient with grade 4 myelo-
suppression with fever would have TTB = 6.0. Using
the conventional approach of defining a single binary
outcome Y indicating at least one grade 3 or 4 toxi-
city, these two patients would be scored identically,
with both having Y = 1.
The posterior expected TTB of dose x is
τ(x,Dn) = E(TTB |x,Dn)
(17)
=
J∑
j=1
mj∑
k=1
wj,kE{pij,k(x, θ)|Dn}.
The trial is conducted by establishing a targeted
total toxicity burden, TTB∗, and choosing each co-
hort’s x to minimize |τ(x,Dn)−TTB
∗|. This is anal-
ogous to choosing a dose, based on a binary Y with
pi(x, θ) = Pr(Y = 1|x, θ), using the CRM criterion to
minimize |E{pi(x, θ)|Dn}−pi
∗| for given target prob-
ability pi∗. It is easy to show that, since wj,k−1 <wj,k
and βj,1 > 0 for all j and k, τ(x,Dn) is increasing in
x, so x may be determined by a monotone search.
The process proposed by BT for establishing the
target TTB∗ is straightforward, albeit somewhat
elaborate. The physicians are first asked to spec-
ify a set of hypothetical patient cohorts and toxic-
ity outcomes for each patient in each cohort, with
the cohorts defined so that the toxicity severities
vary substantially between cohorts. BT provide a
detailed description of this process, and in the sar-
coma trial there were 16 hypothetical cohorts of 4
patients each with the mean TTB of each cohort
varying from TTB = 1.25 to 5.62. For each hypo-
thetical cohort, the oncologists are asked whether
observing its toxicity outcomes would lead them to
escalate, repeat the current dose, or de-escalate for
the next cohort. The target TTB∗ is then defined as
the mean of the TTB values for which the decision
would be to repeat the current dose. For the sarcoma
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Fig. 4. The elicited toxicity severity weights used in the soft tissue sarcoma trial.
trial, this yielded TTB∗ = 3.04. Computer simula-
tions of this methodology provided by BT show that
it has remarkably attractive OCs and makes deci-
sions very differently from conventional phase I de-
signs. A cohort of four patients all with myelosup-
pression grade 4 without fever, patients #1, # 2
and # 3 with grade 3 fatigue, and patient #4 with
grade 3 nausea/vomiting would have TTB = {(1.5+
0.5)+(1.5+0.5)+(1.5+0.5)+(1.5+1.5)}/4 = 2.25.
The three oncologists all agreed that the appropriate
decision based on these outcomes would be to esca-
late, whereas any conventional method based on one
binary toxicity indicator would score this as 4 “toxi-
cities” in 4 patients and certainly would de-escalate.
6. OPTIMIZING DOSE AND SCHEDULE
6.1 A New Paradigm for Phase I Trials
Braun et al. (BTND, 2007) proposed a new
paradigm for phase I trials that jointly optimizes
schedule of administration and per-administration
dose (PAD) based on time-to-toxicity. This extends
Braun, Yuan and Thall (2005), who optimized sched-
ule while assuming a fixed PAD. Although the model
used by BTND is very different from that underlying
the TiTE CRM (Cheung and Chappell, 2000) for
dose-finding based on time-to-toxicity, the BTND
method is a practical extension in that it allows
schedule as well dose to be varied. The treatment
regime is x= (s, ds), where s= (s1, . . . , sk) are suc-
cessive administration times and ds = (d(s1), . . . , d(sk))
are the doses given at those times. BTND address
the problem of evaluating a K × J matrix of K
nested schedules, s(1) ⊂ s(2) ⊂ · · · ⊂ s(K), where the
kth schedule is s(k) = (s1, s2, . . . , sm(k)), so thatm
(1) <
m(2) < · · · <m(K), and J PADs, d(1) < d(2) < · · ·<
d(J). The treatment set evaluated by the design is
X = {(s(k), d(j)) :k = 1, . . . ,K, j = 1, . . . , J}, and the
total amount of the agent given to the patient in-
creases with both dose and schedule. For example,
a patient assigned PAD d(3) under schedule s(2) =
(s1, s2, . . . , sm(2)) receives total dose d
(3)m(2) of the
agent inm(2) successive administrations of d(3) each,
unless therapy is terminated early due to toxicity, so
the planned ds(2) in x= (s
(2), ds(2)) is them
(2)-vector
with all entries d(3).
For this regime, it is helpful to distinguish between
two time scales, study time and patient time. Start-
ing at study time 0 when the trial begins, let e be a
given patient’s entry time, so that the patient’s as-
signed schedule s is administered at study times e+
s= (e+ s1, . . . , e+ sk). Denote a patient’s time from
entry at e to toxicity by T , so that at study time t
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the patient’s observed time to toxicity or last follow-
up is T o(t) = T if e+ T ≤ t and T o(t) = t− e if e+
T > t. Defining δ(t) = I(e+T ≤ t), the patient’s out-
come data at study time t are Y (t) = (T o(t), δ(t)).
The probability model is constructed from the pa-
tient’s hazard of toxicity, h(u|d, θ), associated with
a single administration of dose d given u days pre-
viously, and we denote H(x|d, θ) =
∫ x
0 h(u|d, θ)du.
Under the assumption that effects of successive ad-
ministrations of the agent are additive, the overall
hazard of toxicity at study time t for a patient en-
tering at e and treated with x= (s, ds) is
λ(t|e, (s, ds), θ) =
k∑
j=1
h(t− e− sj|d(sj), θ),(18)
where h(u|d, θ) = 0 for all u < 0. The patient’s cu-
mulative hazard of toxicity at study time t is thus
Λ(t|e, (s, ds), θ) =
k∑
j=1
H(t− e− sj |d(sj), θ),(19)
and the probability that the patient has not had tox-
icity by study time t is Pr(e + T > t|e, (s, ds), θ) =
exp{−Λ(t|e, (s, ds), θ}. Thus, h and H are expressed
in terms of patient time, whereas λ and Λ are ex-
pressed in terms of study time. The probability dis-
tribution of T is determined by the particular form
of the single administration hazard function h.
The model allows each patient’s actual x= (s, ds)
received to fall outside the set of KJ treatment con-
figurations in X , provided that each dose in ds is
an element of {d(1), . . . , d(K)}. In particular, the el-
ements of ds need not be identical. This accommo-
dates the possibility that a patient’s treatment does
not go as planned, for example, due to interim dose
reductions following moderate toxicity or deviations
from the planned schedule. It also allows the possi-
bility that the patient’s planned x may be changed
before the schedule is completed, based on other pa-
tients’ data observed during the patient’s therapy.
At study time t, let xi(t) denote the portion of the
ith patient’s treatment regime xi that has been ad-
ministered by that time and let Dt = {(T
o
i (t), δi(t),
ei, xi(t)), i= 1, . . . , n(t)} denote the current data. The
likelihood at study time t is
L(Dt|θ) =
n(t)∏
i=1
{λ(T oi (t)|ei, xi(t), θ)}
δi(t)
(20)
· exp{−Λ(T oi (t)|ei, xi(t), θ)}.
BTND assume that, for each j = 1, . . . , J, the single-
administration hazard function associated with dose
d(j) is a triangle, formally
h(u|d(j), θj) =
2αju
(βj + γj)βj
I(0≤ u≤ βj)
+
2αj(βj + γj − u)
(βj + γj)γj
(21)
· I(βj < u≤ βj + γj),
where θj = (αj , βj , γj), so that θ = (θ1, . . . , θJ) has
3J elements. The jth triangle has base of length βj+
γj , area αj , and maximum height h(βj |d
(j), θj) =
2αj/(βj + γj). Thus, for u≥ βj + γj , the cumulative
single-administration hazard is Hj(u|d
(j), θj) = αj .
Under this model, since any schedule (s1, . . . , sk) is
finite, given θ and k-vector of PADs ds = (d
(j), . . . ,
d(j)), the cumulative hazard Λ(t|(s, ds), θ) has the
finite maximum value kαj . Consequently, given θ,
the probability that the patient never experiences
toxicity is F¯ (t|(s, ds), θ) = exp(−kαj) for all t > sk+
βj + γj, with the obvious elaboration of the upper
limit on F¯ (t|(s, ds), θ) if the elements of ds are not
identical.
The triangular form of h may seem to be an over-
simplification of a complex phenomenon. In appli-
cation, however, it is quite flexible and yields a very
robust trial design. Figure 5 shows the cumulative
hazard of toxicity for a patient treated with a fixed
PAD according to the 4-administration schedule s=
(0,3,10,13). The shaded area represents H(12), the
cumulative hazard of toxicity by day 12. The smooth-
ness of the curve H(u) for 0 ≤ u ≤ 40 that results
Time (in days)
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Fig. 5. Illustration of triangular component hazards for ad-
ministrations on days 0, 3, 10 and 13, and the resulting cu-
mulative hazard function. The shaded region is the cumulative
hazard, H(12), of toxicity by day 12.
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from summing four triangles and the fact that the
parameters (αj , βj , γj) characterizing the jth trian-
gle corresponding to d(j) are estimated from the ac-
cumulating data together provide an intuitive mo-
tivation for the model’s flexibility and robustness.
This was borne out by the extensive simulation stud-
ies reported by BTND. In the setting where only
schedule is varied with PAD fixed, Liu and Braun
(2009) have studied the use of a smooth component
hazard function, a 2-parameter Weibull, h(u|α,β) =
eβαuα−1 exp(−uαeβ) for u > 0, where α > 0 and β
is real-valued. This allows h to be nonmonotone if
α≥ 2 or decreasing if 0≤ α < 2.
6.2 Trial Conduct
Given an interval [0, t∗] large enough to reliably
evaluate T under the longest schedule, the physi-
cian specifies a target pi∗ = Pr(T ≤ t∗). For brevity,
I will temporarily index a patient’s assigned treat-
ment (s(k), d(j)) by (k, j), and denote the c.d.f. of
T associated with x = (k, j) by Fk,j(θ) = Pr(T ≤
t∗|(k, j), θ). Since L(Dt|θ) and hence the posterior
p(θ|Dt) change continuously with t during the trial,
necessarily, x ∈ X is chosen for each newly enrolled
patient, that is, c = 1. A patient accrued at study
time t is assigned the pair (k, j) ∈ X minimizing the
objective function |E{Fk,j(θ)|Dt} − pi
∗|, similar to
the CRM. Assignment of x using this criterion is
subject to the following two safety rules. Given a
maximum toxicity probability, Fmax , specified by
the physician, the schedule-dose pair (k, j) is ac-
ceptable if Pr(Fk,j(θ)>Fmax |Dt)< p
∗, where p∗ is a
fixed upper cut-off such as 0.80 or 0.90. If no pair in
X is acceptable, the trial is stopped. This is similar
to the toxicity portion of the acceptability criteria
(8) of the EffTox methodology. The second safety
rule is that escalation from (k, j) is restricted in
that no untried dose-schedule combination may be
skipped, specifically the next patient may be treated
at x= (k + 1, j), (k, j + 1) or (k + 1, j + 1), but at
no higher pair. There is no such constraint on de-
escalation. While developing this methodology, we
initially tried using the more restrictive constraint
that does not allow diagonal escalation, from (k, j)
to untried (k + 1, j + 1), but this yielded a design
with very poor properties. This is the case essen-
tially because this constraint makes exploration of
the 2-dimensional set of KJ schedule-PAD pairs un-
feasible, and, in fact, it provides no additional mea-
sure of safety. While BTND recommended that the
first patient be treated at the safest pair (k, j) =
(1,1), in practice, the physician might wish to start
at (1,2), (2,1) or (2,2).
It may seem self-evident that this method is greatly
superior to any comparable method that fixes sched-
ule and only varies dose, since an optimal combina-
tion (s(k), d(j)) is simply ignored if the fixed sched-
ule is not s(k). The simulations reported by BTND
clearly illustrate this point. Currently, however, it
still is standard practice in phase I trials to guess
what schedule might be best, possibly based on an-
imal data, and proceed in humans by varying only
dose. As described by BTND, this new methodology
has been used to conduct an allotx trial of the post-
transplant agent 5-azacitidine, which is thought to
kill leukemia cells by reactivating tumor suppressor
genes while also enhancing graft-versus-leukemia ef-
fect.
7. DISCUSSION
Each of the designs reviewed here includes one or
more more aspects of treatment or outcome in an
early phase trial that are ignored by standard de-
signs. The price of accommodating such additional
complexity is a much more structured model and
method. This often requires substantially more work
for trial design and conduct, including analysis of
historical data, elicitation of priors and design pa-
rameters, development of computer software, car-
rying out simulations to calibrate design parame-
ters and establish operating characteristics, and the
difficult process of real time data monitoring dur-
ing trial conduct. In each case, however, the design
provides advantages over standard methods so large
that the comparisons may seem unfair. Evidently,
accounting for both anti-disease effect and toxicity
is a good idea, ignoring covariates is a bad idea,
quantifying the clinical importance of different types
and grades of toxicities is a good idea, and ignoring
schedule effects is a bad idea. For example, the op-
timal treatment pair determined by the design in
the 5-azacitidine trial was (40 mg/m2 per adminis-
tration, 3 cycles), which simply could not have been
found using a conventional dose-finding method that
fixes schedule at 1 cycle. While each of the designs
relies on a model with a nontrivial number of param-
eters, which in turn often requires elaborate prior
specification and sophisticated numerical methods,
the amount of information per patient also is much
greater. The final questions are whether such designs
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have good properties, which the computer simula-
tions show they do, and whether they can be imple-
mented in practice, which has been the case for all
of the designs discussed here.
For most early phase trials, conventional meth-
ods for determining sample size based on hypothesis
testing or estimation may be of little use. To deter-
mine a planned maximum sample size for a phase
I or I/II trial, I ask the physicians the anticipated
accrual rate, which often is a range of values, the
desired maximum trial duration, and cost or other
resource limitations, such as the amount of a spe-
cialized agent that feasibly can be produced in the
laboratory. For each of several feasible maximum
sample sizes, I simulate the trial and also compute
posterior estimates of important parameters based
on illustrative data sets. I then show these results to
the physician and ask him/her to choose a maximum
sample size on that basis. If the largest feasible sam-
ple size does not yield a reasonably reliable design,
I recommend that the trial not be conducted. Using
this practical approach, in my experience planned
phase I or I/II sample sizes usually range from 24
to 60.
The most severe difficulties in achieving widespread
implementation of outcome-adaptive methods in early
phase clinical trials are computational and sociologi-
cal. The first practical requirement is portable, high
quality computer software for implementation, in-
cluding statistical programs that perform the neces-
sary computations for specific methods and, ideally,
graphical user interfaces that communicate with es-
tablished databases and statistical programs to facil-
itate real-time data entry and computation of adap-
tive decision criteria during the trial. An “elephant
in the living room” of outcome-adaptive methods for
clinical trials is that constructing and implementing
such information systems in medical environments
is often much more difficult, expensive and time-
consuming than developing a particular statistical
method. Moreover, once such a system is in place,
the process of entering the patient data required by
an outcome-adaptive method is time-consuming and
potentially error prone.
A natural question is whether one can construct
practical designs that address the problems that arose
in the SCT trial described in the Introduction. Such
designs would optimize multiple schedule-dose com-
binations of several agents used in combination based
on a vector of appropriately chosen efficacy and tox-
icity outcomes, possibly accounting for patient co-
variates and schedule-dose-covariate interactive ef-
fects on the outcomes, while adaptively choosing
patient-specific schedule-dose combinations in real
time. This also would require a decision criterion
based on multiple outcomes, possibly using either
efficacy-toxicity trade-offs or numerical utilities
(Houede et al., 2010). Currently, we are working to
develop new designs that include various combina-
tions of these extensions. In my experience, how-
ever, early phase trials are so complex that most
trials cannot be optimally designed until after they
already have been carried out, and a “one size fits
all” design simply does not exist.
Clinical trials are viewed very differently by the
pharmaceutical companies who produce and supply
new agents, by regulatory agencies, by institutional
review boards, by administrators who provide in-
frastructure and resources for trial conduct, by the
physicians and nurses who actually treat the pa-
tients in a trial, and by the patients themselves. In-
dividuals with decision-making authority in all of
these different groups must agree on a trial design
before a trial may be conducted. Many of these peo-
ple regard the structure and properties of a partic-
ular statistical design as technicalities too compli-
cated to understand and at most marginally rele-
vant. Most early phase trials are conducted using
very simple conventional methods that do not re-
quire computers and are easy to implement. Ac-
counting more fully for the complexities of both the
actual treatment regimes and the patients’ clinical
outcomes is a double edged sword, since the greater
safety and reliability that such methods provide is
obtained only by working much harder in both de-
sign formulation and trial conduct. Physicians who
understand the advantages of properly constructed
outcome-adaptive designs and want to use such meth-
ods are a minority, although they often provide the
initial motivation for developing new statistical de-
signs. Their desire to use outcome-adaptive meth-
ods, and the recent shift in the pharmaceutical com-
munity, at least among statisticians, to embrace all
things “adaptive” in clinical trials seem to be
harbingers of a different future. How this may ac-
tually translate into practical reality in the coming
years remains to be seen.
The website http://biostatistics.mdanderson.org/
SoftwareDownload contains computer programs for
implementing the methods described in Sections 2
(ToxFinder), 3.1 and 3.2 (EffTox) and 5 (Dose Sched-
ule Finder).
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